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Burden, timing and causes of maternal 
and neonatal deaths and stillbirths in sub–
Saharan Africa and South Asia: protocol for a 
prospective cohort study
Objectives The AMANHI mortality study aims to use harmonized 
methods, across eleven sites in eight countries in South Asia and sub–
Saharan Africa, to estimate the burden, timing and causes of mater-
nal, fetal and neonatal deaths. It will generate data to help advance 
the science of cause of death (COD) assignment in developing coun-
try settings.
Methods This population–based, cohort study is being conducted in 
the eleven sites where approximately 2 million women of reproduc-
tive age are under surveillance to identify and follow–up pregnancies 
through to six weeks postpartum. All sites are implementing uniform 
protocols. Verbal autopsies (VAs) are conducted for deaths of preg-
nant women, newborns or stillbirths to confirm deaths, ascertain tim-
ing and collect data on the circumstances around the death to help 
assign causes. Physicians from the sites are selected and trained to use 
International Classification of Diseases (ICD) principles to assign 
CODs from a limited list of programmatically–relevant causes. Where 
the cause cannot be determined from the VA, physicians assign that 
option. Every physician who is trained to assign causes of deaths from 
any of the study countries is tested and accredited before they start 
COD assignment in AMANHI.
Importance of the AMANHI mortality study It is one of the first to 
generate improved estimates of burden, timing and causes of mater-
nal, fetal and neonatal deaths from empirical data systematically col-
lected in a large prospective cohort of women of reproductive age. 
AMANHI makes a substantial contribution to global knowledge to 
inform policies, interventions and investment decisions to reduce 
these deaths.
The past two decades have seen significant global declines in both ma-
ternal and child mortalities. These declines may be attributable, in part, 
to the attention they received due to the millennium development goals 
(MDGs) [1]. However, gains have not always been realized in areas with 
the highest burden. Three million neonatal deaths, 2.6 million stillbirths 
and over 280 000 maternal deaths still occur annually [2]. The vast ma-
jority (99%) of these deaths continue to occur in low– and middle–in-
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come country settings (LMICs); a disproportionate 85% 
occur in South Asia and sub–Saharan Africa alone [3,4].
An incomplete understanding of the burden, timing and 
causes of maternal, fetal (stillbirths) and neonatal deaths 
remains a major challenge in addressing mortality in moth-
ers and their newborns. In many LMICs, routine vital reg-
istration systems are lacking or incomplete. Facility and 
community data are often not systematically collected and 
medical death certification systems are non–functional. For 
example, in sub–Saharan Africa and South Asia, less than 
12% of countries meet criteria for reasonably complete 
cause of death reporting [5].
Given these limitations, methods to directly estimate mor-
tality have been developed [6]. These estimates rely on na-
tional surveys, demographic surveillance systems or sam-
ples of populations to determine causes of deaths [6–10]. 
While they provide a basis for action, these estimates are 
subject to biases and limitations of the data sources and 
may over– or under–estimate the true burden of these 
deaths [11,12]. Sadly, these are the only sources of evidence 
to inform planning, prioritization and distribution of re-
sources in many LMICs [12].
OBJECTIVES
The Alliance for Maternal and Newborn Health Improve-
ment (AMANHI) mortality study aims to determine the 
burden, timing and causes of maternal deaths, stillbirths 
and neonatal deaths using harmonized methods across 
eleven sites in sub–Saharan Africa and South Asia. This 
prospective study, centrally coordinated by the department 
of Maternal, Newborn Child and Adolescent Health of the 
World Health Organization (WHO/MCA), uses harmo-
nized tools, training and implementation strategies across 
participating sites to collect data from a large cohort of 
women of reproductive age, their pregnancies and the out-
come of these pregnancies for both mothers (up to 42 days 
postpartum) and their newborns (till end of the neonatal 
period). The study will also assess the comparability of the 
estimates generated from these prospectively collected data 
with existing model–based estimates of maternal mortality, 
stillbirths and neonatal mortality. The data will also be used 
to test other innovative approaches (including computer–
based “machine learning” methods) to estimate the causes 
of these deaths. This manuscript describes the protocol for 
the AMANHI mortality study highlighting key steps that 
have been implemented to ensure reliability and external 
validity of the findings.
METHODS
AMANHI is a multi–centre, multi–country, population–
based, cohort study in which women of reproductive age 
are followed through pregnancy, childbirth and the post-
natal period. The AMANHI mortality study includes sites 
from Bangladesh (Sylhet), India (Haryana and Uttar 
Pradesh), Pakistan (Karachi and Matiari) in South Asia; and 
Democratic Republic of Congo (Equator), Ghana (Kintam-
po), Kenya (Western province), Tanzania (Ifakara and Pem-
ba) and Zambia (South Zambia) in sub–Saharan Africa. A 
summary description of the sites’ characteristics is provid-
ed in Table 1. All the sites involved in the AMANHI mor-
tality study were those that had planned or on–going stud-
ies on neonatal health funded by the Bill and Melinda Gates 
Foundation. All these studies planned to enrol greater than 
5000 pregnant women, and had established a surveillance 
system for identifying all pregnant women in a geographi-
cally defined area. They also planned to follow up pregnant 
women through pregnancy and up to 72 hours after birth.
Training for harmonized implementation
The AMANHI mortality study teams undertook two main 
training sessions, facilitated by experts from the WHO, in 
Geneva Switzerland to harmonize the implementation of 
study procedures. The first session in June 2012 involved 
principal investigators from sites. At this training work-
shop, sites developed common data collection tools (core 
variable tables) and implementation strategy. Sites adapted 
the generic protocol to suit their context and submitted to 
the Ethics review committees of the WHO/MCA and other 
relevant institutions.
In August 2014, AMANHI brought together two site coor-
dinators per site for a week–long training to harmonize phy-
sician assignment of causes of deaths (CODs). Participants 
used principles of the International Statistical Classification 
of Diseases (ICD) to assign CODs and complete death cer-
tificates. Participants used these principles contained in an 
AMANHI VA manual to practice until they assigned the 
same CODs for five consecutive forms. These participants, 
in turn, trained physicians in their respective sites.
Mortality surveillance
The AMANHI mortality surveillance utilizes an existing 
1–6 monthly routine household surveillance visits by 
trained fieldworkers to over 2 million women of reproduc-
tive age across sites to identify and follow–up pregnant 
women through pregnancy, childbirth to 42 days postpar-
tum. The surveillance comprises active and passive com-
ponents. In the former, fieldworkers identify pregnant 
women, obtain their consent and enrol them for follow–up, 
providing them with unique study identification numbers 
(study ID). The study will therefore obtain data on all wom-
en who become pregnant, every pregnancy and their out-
comes (including abortions/miscarriages, stillbirths and 
livebirths). These will serve as denominators for estimating 
rates of maternal, fetal and neonatal mortality. Fieldwork-
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ers record all maternal, fetal/stillbirth or neonatal deaths 
that occur among enrolled participants during surveillance 
visits. A listing of these deaths is used by specially trained 
supervisors for the VA interviews. This list will be used to 
generate numerators for the mortality rate estimates after 
the type (maternal, pregnancy–related, fetal or neonatal) 
and timing (details below) are confirmed from the VA in-
terviews. Fieldworkers also collect baseline socio–demo-
graphic data and assets inventory for classifying house-
holds into wealth quintiles. This will allow for evaluation 
of inequities in the distribution of mortality burden within 
the population.
The primary study outcomes include all–cause maternal 
mortality ratio (MMR) defined as number of women who 
die whilst pregnant or within 42 days of a pregnancy’s end, 
irrespective of the duration or site of the pregnancy per 
100 000 livebirths. Stillbirth rate (SBR) will also be calcu-
lated either as the number of stillbirths per 1000 births 
(true rate) or per 1000 livebirths (ratio). Neonatal mortal-
ity rate (NMR) will be defined as the number of deaths 
among live born infants within the first 28 days after birth 
per 1000 live births. Timing of maternal deaths will be clas-
sified as deaths in early pregnancy, late pregnancy, intra-
partum, immediate postpartum and late postpartum; still-
births will be classified as antenatal or intrapartum and 
neonatal deaths by day of death for each day in the first 
week after birth and then weekly till day 28. Cause–spe-
cific mortality rates/fractions will also be determined. The 
data will also be disaggregated and rates estimated sepa-
rately for sub–Saharan Africa and South Asia.
In nine of the eleven sites where a maternal morbidity sur-
veillance runs concurrently, women receive five scheduled 
visits–three in pregnancy and two postpartum. Mortality 
surveillance is incorporated into these visits. The field-
workers review health facility records to identify mortality 
events for VA interviews. In the interval between visits, 
families report deaths or pregnancy losses to AMANHI for 
follow–up (passive surveillance). The Zambia site is the 
only exception because pregnancy identification is only 
done at antenatal clinics. This approach was used because 
of high antenatal care coverage (over 96%) within the study 
district [13].
The AMANHI Verbal Autopsies: confirming 
type, timing and obtaining causes of deaths
In all sites, when a stillbirth occurs, a baby or woman of re-
productive age dies, trained VA supervisors visit the house-
hold, after the mourning period, and conduct VA interviews 
to obtain detailed information on the circumstances leading 
to the death. The VA supervisors identify a reliable infor-
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Table 1. Summary description of the parent studies, surveillance system, surveillance population and annual number of births at 
AMANHI sites
Site Parent Study title and objective exiSting Pregnancy Surveillance 
SyStem
total Surveillance 
PoPulation
reProductive–
aged women in 
Surveillance
aPProximate 
annual birthS
Bangladesh Aetiology of Neonatal Infection in South Asia 
(ANISA): to estimate community level aetiology–
specific incidence predictive risk factors and clini-
cal features, treatment and prevention strategies for 
serious infections among young infants (0–59 d).
2–monthly by trained com-
munity health workers 
(CHWs)
600 000 88 000 13 000
Democratic 
Republic of Congo 
(DRC)
African Neonatal Sepsis Trial (AFRINEST): to test 
the safety and efficacy of simplified antibiotic reg-
imens for treating possible serious bacterial infec-
tion in 0–59 day–old infants.
3–monthly by CHWs 699 288 65 000 12 000
Ghana Neonatal vitamin A supplementation (NeovitA) 
study: to determine if vitamin A supplementation 
to neonates once, orally, <48 hours of birth will re-
duce neonatal, early and late infant mortality.
Monthly by fieldworkers 700 000 147 000 21 000
India – Haryana NeovitA study: same as Ghana. Monthly by trained CHWs 1 400 000 313 399 34 600
India – Shivgarh Topical emollient application to babies to prevent 
infection especially in pre–terms & ANISA studies.
3–monthly by fieldworkers 1 350 000 184 430 44 000
Kenya AFRINEST study: same as DRC. 3–monthly by CHWs 400 000 30 000 10 000
Pakistan – Karachi ANISA study: same as Bangladesh. 3–monthly by fieldworkers 270 000 63 000 9500
Pakistan–Matiari ANISA study: same as Bangladesh. 3–monthly by fieldworkers 215 200 64 000 8000
Tanzania–Ifakara NeovitA Study: same as Ghana. 3–monthly by fieldworkers 300 000 72 000 6000
Tanzania–Pemba Chlorhexidine (CHX) study: to evaluate the effi-
cacy of chlorhexidine cord cleansing on neonatal 
mortality.
6 weekly by trained CHWs 390 000 72 000 14 000
Zambia* Chlorhexidine (CHX) study: to evaluate the effi-
cacy of chlorhexidine cord cleansing on neonatal 
mortality.
No pregnancy surveillance; 
facility ANC enrolment
25 000 25 000 9000
*Zambia to recruit only from antenatal clinics.
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mant, defined as any person who lived closely with the de-
ceased in the period immediately preceding the death and 
who is capable of providing reliable and coherent account 
of the circumstances leading to the death, for the interview. 
The objectives for administering the AMANHI VAs are 
three–fold: first, to confirm deaths and the type of death es-
pecially the critical discrimination between maternal or 
pregnancy–related deaths (for women) and between still-
births and early neonatal deaths. Second, the VAs will also 
confirm the timing of the deaths as described in the previ-
ous section. The third objective is to assign causes to the 
deaths. AMANHI uses a uniform tool and harmonised 
methods for the collection and interpretation of the VA data.
The AMANHI VA tool
Principal investigators from each site, together with the 
WHO/MCA coordinating team, developed a table of core 
variables to be collected across sites for all deaths. These 
variables were derived from three existing tools: the WHO 
VA [14], InterVA [15] and SMARTVA (Tariff method) [16] 
tools. The WHO tool was used as the template and ques-
tions from the other tools were added if they were not al-
ready in this template. When questions were found to be 
similar but response options differed between tools, both 
questions were maintained in the AMANHI tool. This will 
allow for data generated in AMANHI to be analysable us-
ing these top two available software platforms (InterVA and 
SMARTVA). The AMANHI core variable table therefore in-
cludes questions to be asked, the response options and how 
variables should be captured in the final common study 
database. This harmonised data collection tool will also fa-
cilitate pooling of data across sites and hence increase sta-
tistical power for analysis on rarer outcomes.
AMANHI VA interviews–form completion
Questions in core variable tables were translated into site–
specific questionnaires in three sections: a narrative, close–
ended questions and records review and data abstraction 
sections.
Semi–structured narratives. Interviewers ask respon-
dents to provide detailed, chronological narratives on the 
circumstances leading to the death. Where needed, they 
further probe for specific details about current or any preg-
nancies that had ended around the time of death; the onset 
of any illness, signs and symptoms exhibited, any pre–ex-
isting medical conditions and care–seeking during the 
pregnancy and/or fatal illness. Irrespective of pregnancy 
outcomes, interviewers probe into pregnancy and labour 
history, whether a baby was stillborn or died after birth. 
Where technical or local words are used for signs they 
probed and write down what the respondent meant rather 
than their own interpretations.
Close–ended questions. Interviewers collect basic demo-
graphic and socio–economic characteristics of the deceased 
and systemically elicit responses for all signs and symptoms 
that the deceased exhibited before death. These close–end-
ed questions as well as providing details on some of the 
signs and symptoms also elicit important signs and symp-
toms that respondents may not mention in the narratives. 
For instance, for haemorrhage, they probe for the onset, 
severity, duration and any care sought and the outcomes of 
the care–seeking. In case the narrative conflicts with the 
close–ended responses, interviewers probe further to en-
sure data are internally consistent.
Records review and abstraction. Interviewers abstract 
relevant data from hospital, antenatal, childbirth, postpar-
tum clinic attendance records or death certificates onto the 
VA questionnaire.
Interpreting AMANHI VAs through 
harmonised assignment of causes of deaths
The AMANHI mortality study uses harmonized protocols 
(in an AMANHI VA manual) to assign CODs. This is to im-
prove objectivity and transparency of the COD assignment 
and increase validity and reliability of physician–assigned 
causes. The manual provides uniform criteria and process-
es for selection and training of physicians; common defini-
tions and procedures for assigning causes [17]; centralised 
accreditation and certification of trained physicians and 
streamlining the entire process on a specially–designed 
software platform.
Training and accreditation of physicians. PIs and study 
coordinators recruited and trained selected local physicians 
on the principles of AMANHI VA using the VA manual. A 
list of all trained physicians is then submitted to the WHO/
MCA for accreditation. The trained physicians were pro-
vided online access to 20 standardised VA forms (still-
births/neonatal – 12 and women of reproductive age – 8) 
that had CODs assigned by global VA experts. The num-
bers were so selected to reflect the relative frequency of oc-
currence of these deaths as well as provide enough num-
bers to test a variety of cases. Upon completion, the 
physicians submit the forms online to the WHO/MCA who 
compare the physician assigned CODs with the standard 
CODs for agreement. Physicians are only accredited when 
80% or more of their assigned CODs agree with the stan-
dard. The 80% mark was selected because we considered 
that one in every five forms may be difficult to code due to 
poor quality of data. Physicians are given three attempts at 
accreditation and when they fail, they are not allowed to 
assign CODs in AMANHI. After each unsuccessful at-
tempts, coordinators and an expert from WHO retrained 
physicians. AMANHI certificates were given to all accred-
ited physicians.
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Assigning CODs. The study employed ICD principles 
adapted from the revised WHO Verbal Autopsy Coding 
Standards (2012) [14,17]. A list of programmatically–rele-
vant causes of maternal, fetal and neonatal deaths (Table 2, 
Table 3 and Table 4) were selected and their operational 
definitions for AMANHI were specified. When the cause is 
known but not included in the AMANHI list, an option is 
given to code as such or as indeterminate if no COD can be 
assigned.
Procedure for consensus building. The AMANHI algo-
rithm for the process of consensus building around CODs 
is shown in Figure 1. The underlying cause of death 
(UCOD) assigned by physicians is used for consensus 
building. In AMANHI, at least two out of four physicians 
must agree on a cause to be assigned as final UCOD. Phy-
sicians are classified at two levels based on clinical and pre-
vious VA coding experience. Two level 1 physicians (prac-
titioners who routinely manage pregnant women and 
newborns) first code each VA form independently followed 
by a third level 1 physician if their assigned UCODs differ. 
When all three level 1 physicians do not agree, the form is 
elevated to a level 2 physician (specialists in obstetrics, neo-
natal or child health and/or very experienced in VA coding) 
for arbitration. If the level 2 physician agrees with the 
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Figure 1. Algorithm for consensus building around cause of 
death in AMANHI.
Table 2. AMANHI list of underlying causes of pregnancy–related 
deaths
Underlying cause of pregnancy–related deaths:
Ectopic pregnancy
Abortion–related death
Pregnancy–induced hypertension (pre–eclampsia)
Pregnancy–induced hypertension (eclampsia)
Obstetric haemorrhage (antepartum)
Obstetric haemorrhage (postpartum)
Obstructed labour
Ruptured uterus
Pregnancy–related sepsis (antepartum)
Pregnancy–related sepsis (postpartum)
Severe anaemia
Pre–existing medical conditions exacerbated by pregnancy
Accidents/injuries
Other specific obstetric causes
Other specific NON–OBSTETRIC causes
Cause not possible to determine from verbal autopsy
Other significant conditions contributing to death:
Anaemia
Severe malnutrition
HIV
Maternal age <15 years
Maternal age >35 years
Table 3. AMANHI list of underlying causes of neonatal deaths 
and contributing conditions
Underlying cause of neonatal death:
Preterm birth complications
Perinatal asphyxia
Neonatal pneumonia
Neonatal sepsis/meningitis
Neonatal tetanus
Congenital malformations
Neonatal diarrhoea
Accidents/injuries
Other specific perinatal causes
Cause not possible to determine from verbal autopsy
Other conditions contributing to neonatal death:
Term low birthweight (small for gestational age)
Prematurity
Maternal condition leading to neonatal death:
Pregnancy–induced hypertension (pre–eclampsia)
Pregnancy–induced hypertension (eclampsia)
Obstetric haemorrhage (antepartum)
Obstructed labour
Ruptured uterus
Maternal infection affecting the baby
Pre–existing medical conditions exacerbated by pregnancy
Accidents/injuries
Other obstetric complications (malpresentation, cord prolapse)
Other specific maternal conditions
No identifiable maternal conditions
UCOD assigned by any of the level 1 physicians, that cause 
is assigned to the death. However, when they do not agree 
with all three, the form is coded as indeterminate. The lev-
el 2 physicians also determine whether it was a neonatal or 
Maternal, fetal (stillbirths) and neonatal mortality cohort study
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fetal death and, for the latter, whether it was ante– or in-
trapartum. All physicians also assign immediate and ante-
cedent causes of deaths for each VA death certificate and 
specify co–existing significant pathologies/conditions that 
might have contributed to the death. They draw a flow di-
agram to explain the link between UCOD and the anteced-
ent and immediate cause(s).
AMANHI verbal autopsy software and quality control 
of the coding process. A customized software platform was 
developed by the Community Empowerment Laboratory 
(Lucknow, Uttar Pradesh, India), in collaboration with 
WHO/MCA to facilitate the COD assignment. The software 
helps to coordinate and manage the coding process. It has 
in–built algorithms to automate the assignment of forms to 
physicians and for the consensus–building process (Figure 
1). Its user interface groups clinical signs and symptoms 
on the VA form according to physiological systems or/and 
stages of pregnancy. It also provides physicians with the 
template to construct the flowchart on the mechanism of 
the death and mandates them to complete a death certifi-
cate for each death, providing the list of UCODs in a drop-
down menu. As a monitoring tool, site coordinators have 
a visual display of the frequency of agreement between each 
physician and the final UCOD for every form they code 
and this is used as proxy index to guide refresher training 
needs of physicians.
Quality monitoring
AMANHI–specific quality control procedures include 
physical presence of study supervisors to directly observe 
5% VA interviews as they are being conducted in the field. 
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Table 4. AMANHI list of types and underlying causes of fetal 
deaths (stillbirths) and contributing conditions
Maternal/foetal underlying condition:
Congenital malformations
Pregnancy–induced hypertension
Gestational diabetes
Antepartum haemorrhage
Maternal infections that can affect the foetus
Maternal medical conditions (diabetes, epilepsy, etc.)
Maternal accident/injury
Obstructed labour
Other obstetric complications (malpresentation, cord prolapse)
Other specific perinatal causes
Cause not possible to determine from verbal autopsy
Other conditions contributing to the stillbirth:
Small–for–date baby
Multiple pregnancy
Post–date (>10 months)
Maternal age <15 years
Maternal age >35 years
Obesity
Severe malnutrition
Smoking, alcohol or drug abuse
They then provide prompt feedback on fieldworker per-
formance. Also, immediately after collection on the field, 
data are manually checked for completeness and consis-
tency before transmission for data entry. The WHO/MCA 
sends experts on 6–monthly site visits to monitor quality 
of implementation. AMANHI mandates every site to sub-
mit monthly progress report and transmit all collected data 
every quarter for quality review and feedback.
Sample size considerations
Approximately 263 000 pregnant women will be enrolled 
into the mortality study across the 11 sites: about 126 000 
from sub–Saharan Africa and 137 000 from South Asia. Sam-
ple size considerations were based on maternal mortality, 
given the rarity of this outcome. Estimated regional MMRs 
for sub–Saharan Africa and south Asia, pooled from the in-
cluded countries, were 435 and 290 per 100 000 livebirths 
respectively (Table 5). With these sample sizes, AMANHI 
would have more than 90% power, at the 5% significance 
level, to detect all–cause mortality with a precision of ±8% 
for sub–Saharan Africa and ±10% for south Asia, with a 
higher precision for the pooled sample across all sites. The 
study will also have adequate power to quantify any single 
cause that accounts for at least 20% mortality (within ±15%). 
Considerations for country–specific samples sizes are shown 
in Table 5. With relatively more common outcomes such as 
stillbirths and neonatal deaths these sample sizes will guar-
antee highly precise mortality rate estimates overall and for 
regions and countries.
Data management
Data are collected using paper–based forms or tablet–based 
software with the exception of Zambia where field moni-
tors collected data using forms designed in the TeleForms® 
system (HP, Cambridge, UK). After supervisors in Zambia 
review forms for completeness, they scan them, enter and 
Table 5. Site specific sample size for all cause maternal mortality
Study Site SamPle Size eStimated 
maternal 
mortality 
ratio/100 000 
live birthS
relative 
PreciSion
Sub region–Sub–Saharan Africa:
Democratic Republic of the Congo 20 000 670 ±17%
Ghana 32 000 250 ±22%
Kenya 22 000 400 ±21%
Tanzania (2 sites) 27 000 360 ±20%
Zambia 25 000 590 ±16%
Sub–Saharan Africa (pooled) 126 000 435 ±8%
Sub–region–South Asia:
Bangladesh 19 000 200 ±32%
India (2 sites) 90 000 325 ±11%
Pakistan (2 sites) 28 000 240 ±22%
South Asia (pooled) 137 000 290 ±10%
AMANHI study group.
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export all the data into an Access database for management. 
Narratives are transcribed in the language of collection or 
directly into English, French, Swahili, Hindi or Urdu. 
Close–ended questions are double–entered independently 
by two clerks into appropriate software with in–built range 
and consistency checks. The double–entry checks against 
entry errors. All data are saved to a dedicated password–
protected server and transferred quarterly to the WHO/
MCA for further consistency checks.
Data analysis
All analyses will be conducted using Stata statistical soft-
ware [18]. Simple tabulations will be done to describe the 
overall burden, timing and causes of deaths–maternal, still-
birth and neonatal. Estimates will also be generated from 
the sub–sample of women who were also part of the pro-
spective morbidity follow–up.
Ethical clearance and informed consent
The AMANHI mortality study received ethical clearance 
from institutional review boards in the participating coun-
tries, host institutions of principal investigators (including 
Johns Hopkins University, University of Kinshasa, London 
School of Hygiene and Tropical Medicine and Boston Uni-
versity) and the WHO. Informed consent is obtained from 
all respondents to the VA interviews.
IMPORTANCE OF THE AMANHI 
MORTALITY STUDY
The AMANHI Mortality study is one of the first to generate 
improved estimates of the burden and timing of maternal, 
fetal and neonatal deaths in sub–Saharan Africa and south 
Asia from empirical data systematically collected in a large 
prospective cohort of women of reproductive age. More 
critically, it will make substantial contributions to global 
knowledge on the causes of these deaths. These improved 
estimates will inform policy, interventions and investment 
decisions to reduce these deaths.
Availability of robust data are critical to intervention design 
and implementation. In resource–limited settings, alloca-
tion of scarce resources requires evidence–based decision–
making which must be informed by reliable data [4,19]. 
Current evidence is derived from estimates from statistical 
models based largely on cross–sectional data, often facility 
based and generated using different methodologies and 
with varying definitions of outcomes. As a result of biases 
in the data, estimates from these models are difficult to val-
idate, limiting stakeholder buy–in and adversely affecting 
their use in planning, intervention design and policy deci-
sion–making [4,12,20].
The AMANHI mortality study has many strengths. It is a 
population–based prospective study which followed up a 
large cohort of women of reproductive age at the commu-
nity level. Data were also collected from the facilities wom-
en attended for deliveries and medical emergencies. This 
will therefore reduce selection biases that might have re-
sulted from using only facility–based data. Perhaps the 
greatest strength is the harmonised implementation across 
all 11 study sites. With the use of common tools and defi-
nitions of variables and outcomes, AMANHI collected con-
text–relevant but uniform data across all sites. This vali-
dates the pooling of the data across the sites to allow for 
analyses on rare outcomes.
The AMANHI approach to assigning causes of deaths stra-
tegically addresses many of the drawbacks in the use of 
physicians including drain on their time and subjectivity. 
The AMANHI VA coding software reduced physician cod-
ing time from 90 minutes to less than 20 minutes per ver-
bal autopsy. This reduced time addresses concerns by some 
advocates that physician times should be better spent in 
actual service delivery [15,21–23]. Besides, whilst auto-
mated computer algorithms have the potential to dramati-
cally improve the speed and efficiency of classifying causes 
and reducing cost [24], incorporating physician’s knowl-
edge of the local context, terminologies and their interpre-
tations in evaluating the causes of deaths is an additional 
advantage that computer–based algorithms may not have. 
Furthermore, the use of the ICD principles, centralised ac-
creditation process, automation of the form assignment to 
physicians and other quality control mechanisms improved 
the transparency and objectivity of the process. The provi-
sion of a limited list of causes and their operational defini-
tions also reduced the occurrence of false discordance be-
tween physicians due to typographical errors.
One major limitation of the AMANHI mortality study is 
generalizability of the results. Data were collected in de-
fined parts of the respective countries; at sites systemati-
cally selected for newborn health interventions because of 
high mortality rates. It is plausible that mortality rates in 
the study areas might not truly represent all regions of the 
participating countries. However, estimates from AMANHI 
will be compared to prevailing estimates for countries. Dif-
ferences may result from several factors such as quality of 
data but will challenge the status quo.
The need for robust empirically generated data to inform 
policy and planning in LMICs is long overdue. By generat-
ing data from a very large cohort of women across eleven 
countries in these two geographic areas with the highest 
mortality burden, AMANHI will provide very precise esti-
mates of mortality, their timing and causes to inform re-
searchers and policy–makers on improved methods for as-
signing cause of death in women and children.
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